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SUMMARY
Aim: To assess the relationships between socio-
demographic factors, quality of life and attitudes
towards psychotropic drugs and dependency and
to compare those relationships in continuous
consumers (CC), occasional consumers (OC) and
non-consumers (NC) of those drugs.
Methods: Quality of life (SF36) and attitudes
(14 statements) were measured in 601 subjects
(45–60 years old) from the SUVIMAX cohort
(SUpple´mentation en VItamines et en sels Min-
e´raux AntioXydants). Data were obtained on 334
NC, 142 CC, 125 OC from the inclusion ques-
tionnaire and the monthly consumption report
notebooks kept by subjects between 1994 and
1998. Dichotomous and polychotomous logistic
regressions were used for the analysis.
Results: The lower the quality of life score the
more frequent was consumption. NC tended to be
men, with high quality of life scores. They enter-
tained negative attitudes towards psychotropics
and dependency. OC tended to be women report-
ing a chronic pathology, with fairly high social
status. They had intermediate quality of life and
denied dependency. CC tended to be men with no
professional activity and low quality of life scores
in particular for mental health and perceived
health. They had positive attitudes towards psy-
chotropics and accept dependency.
Discussion: Assessment of patients’ quality of life
and understanding of their attitudes towards
psychotropics can provide essential informa-
tion for those in charge of health promotion
programmes and may help in identifying new
intervention strategies. Preventive education and
follow-up of therapy may be better suited to the
needs of patients.
Keywords: attitudes, continuous consumers,
dependency, occasional consumers, psychotropic
drugs, quality of life
INTRODUCTION
In the USA and Europe, the increase in use of
psychotropic medication (1, 2) has been shown to be
related to medical factors in women, to socio-
professional factors in men with professional dissa-
tisfaction and a high level of education being
predictive of higher consumption (3), to psycho-
affective factors (social isolation, ability to cope), to
environmental factors (mother being a consumer),
and to social factors (life events) (4). The interna-
tional literature however suggests no investigation
of the relationship between quality of life and con-
sumption of psychotropic medication, although
such a link is plausible.
In all cultures, there are popular beliefs relating to
health and illness. Depending on whether they are
founded on experience of consumption, on beliefs in
the effects of the drugs concerned, and on know-
ledge of mental pathologies, these attitudes may
predispose to consumption (5). As medication has
several meanings rooted in popular beliefs, it
becomes an integral part of the social image that
patients have of themselves. With little information
on the composition and the pharmaceutical action of
the drugs prescribed, the Western consumer views it
as a sort of magic potion dispensed by a ‘witch-
doctor’ with social and legal legitimacy. Popular
culture with regard to medicines and drugs not only
concerns beliefs which serve to interpret the drug,
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but also the drugs themselves in their material form
and the consumer behaviour associated with them.
This complexity explains variability among groups
of psychotropic drug consumers (6).
Knowing about these beliefs is useful for
understanding the cultural basis of behaviour, in
which attitudes are relatively stable dispositions.
Thus in the general population knowing about
therapies is accompanied by a negative attitude
towards psychotropics, which are associated with
representations of doping (7). Recognition of the
calming and relaxing effects of psychotropic
medication leads to users being viewed as weak
individuals. Willpower is preferred for solving
problems (8). Recourse to psychotropics is often
linked to mental disorders resulting from lack of
moral strength and willpower. Conversely, drug
consumption for anxiety and depression is viewed
by family and professionals as being legitimate (9).
Women have more reserved attitudes than men,
and older people have more negative attitudes. The
higher the social status, the less mistrustful are
attitudes towards these drugs. Hostility with regard
to psychotropics goes hand in hand with an attitude
that attributes value to ‘natural’ products, alternat-
ive medicines, and recourse to psychotropics for
social problems. The main arguments against
pharmacotherapy are its side-effects, its undesirable
effects, and possible dependency (10) with some
individuals becoming regularly dependent, and
others succeeding in maintaining intermittent use.
Thus there is not one but several consumer behav-
iours. Duration and regularity of consumption is of
more concern that the act of consumption itself.
A study conducted on psychotropic consumers
in the SUVIMAX cohort1 made it possible to
characterize those with a ‘continuous trajectory’
when reviewed monthly over a period of 5 years,
and those with an ‘occasional trajectory’. This
idea of a trajectory over time was found useful
for assessing dependency and defining consumer
profiles (11). The aim of this study was to assess
the relationships between socio-demographic fac-
tors, quality of life and attitudes towards psycho-
tropic drugs and dependency and to compare
those relationships in continuous consumers
(CC), occasional consumers (OC) and non-con-
sumers (NC) of those drugs.
MATERIALS AND METHODS
This is an observational study carried out by fol-
low-up of a cohort of healthy adults.
Population
Two samples were obtained from the SUVIMAX
cohort participants, which consisted of 5740 healthy
individuals aged from 45 to 60, of whom 340 psych-
otropic were drug users and 5400 were not (12). The
first sample consisted of 267 of the 340 psychotropic
drug users who agreed to participate. Among them
were 142 defined as having a ‘continuous’ trajectory
(CC = consumption every month for 5 years) and
125 as having an ‘occasional’ trajectory (OC = the
remainder) (11). The second sample consisted of 335
of 500 NC randomly selected from the no users, who
agreed to participate NC group.
Measures and data collection
Data were derived from the SUVIMAX inclusion
questionnaire (1994) and from a self-completed
assessment sent by post, which included a quality
of life scale and a set of questions about attitudes
with respect to psychotropic drugs and depend-
ency (1998).
The inclusion questionnaire. The inclusion question-
naire provided socio-demographic and medical
data: gender, professional status (three categories:
executive, non-executive, no professional activity),
socio-cultural status on the basis of educational
level [two groups: up to the baccalaure´at (level
12 years) and beyond], matrimonial status (two
categories: living alone, living with a partner);
history of medical problems or surgery, chronic
pathology (yes/no).
Quality of life scale. The scale used was the MOS 36
Short Form Health Survey (SF36) in its French-lan-
guage version (13, 14). This scale explores eight
dimensions of quality of life: physical functioning
(10 items), role physical (10 items), role emotional
(three items), social functioning (two items), bodily
pain (two items), mental health (five items) vitality
1SUVIMAX (SUpple´mentation en VItamines et sels Mine´raux
AntioXydants) is a controlled randomized primary prevention
trial using nutritional doses of a combination of antioxidant
minerals and vitamins in cardiovasular disease and cancer.
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(four items), and general health (five items). Scores
vary from 0 (worst quality of life) to 100 (optimum
quality of life).
Attitudes towards psychotropic drugs and dependency.
These were explored (15) by 12 statements with four
response choices: complete agreement (1), moderate
agreement (2), moderate disagreement (4), complete
disagreement (5). Non-responses and multiple
responses were classified as ‘neither agree nor dis-
agree’ (3). Four factors, identified by factor analysis,
represented favourable and unfavourable attitudes
to psychotropic drugs, and to dependency. From the
sum of responses, four scores were constituted.
After weighting they range from 0 (least agreement)
to 100 (maximum agreement). For each score, its
internal coherence was measured by calculating
Cronbach’s alpha coefficient (CAC):
Score 1: positive attitudes towards pyschotropic
drugs (four statements) (CAC = 0Æ73);
Score 2: explicit dependency attitudes (three
statements) (CAC = 0Æ71);
Score 3: negative attitudes towards psychotropic
drugs (three statements) (CAC = 0Æ51);
Score 4: implicit dependency attitudes (two state-
ments) (CAC = 0Æ03).
Analysis
The socio-demographic and medical variables, the
eight dimensions of the SF36, and the four attitude
scores were described in the CC, OC and NC
groups by way of frequencies (%) and mean values
(±SD). They were compared between CCs and
OCs, and then for the three groups respectively by
logistic and polychotomous regressions. In both
cases, a univariate analysis was performed,
followed by a multivariate analysis (ascending
stepwise). For each analysis odds ratios (OR) with
95% confidence interval were calculated. The cal-
culations were performed on BMDP software
(Statistical Solutions, Cork, Ireland).
RESULTS
Socio-demographic and medical characteristics of
the samples (Table 1)
The average age of all the study subjects sampled
was about 56 (53 in 1994 and 58 in 1998). A majority
of subject in all three groups, NC, CC and OC, were
living with a partner, had high educational status
and belonged to upper or intermediate social cat-
egories. Less than half had a chronic pathology.
The psychotropic drugs most often consumed were
anxiolytics, antidepressants, hypnotics and neuro-
leptics.
Continuous vs. occasional consumers (Table 2)
Among the socio-demographic and medical varia-
bles, being male, having no professional activity
and use of hypnotics and anxiolytics were inde-
pendently associated with continuous consump-
tion. For quality of life, only mental health was
independently associated with consumption, the
better the level of mental health, the less likely the
subject was to be a CC ()17% for an increase of 10
points in the quality of life score). Three of the four
attitudes showed an independent relationship with
the type of consumption: CCs tended to subscribe
to attitude scores 1, 2, 4.
CCs vs. OCs and NCs (Tables 3 and 4)
Among the initial characteristics, gender, chronic
pathology and the socio-professional category were
independently linked to behaviours. Consumers
were more often women (in particular OCs), more
often declared chronic pathologies, and were more
often in higher socio-professional categories (sig-
nificant for CCs) than NCs. The lower the score for
mental health and general (perceived) health (SF36),
the more likely was the subject to be a consumer,
whether occasional or continuous. Attitude scores
1 and 3 were independently associated with con-
tinuous use (CCs have a higher score 1 and a lower
score 3 than NCs). Attitude score 1 was positively
associated with occasional use, and scores 2, 3 and 4
were negatively associated with occasional use.
DISCUSSION
The poorer the quality of life, the more frequent is
consumption. As these are altered by experience,
quality of life and attitudes towards these medi-
cations and dependency may explain the behav-
iours of the groups under study. NCs tended to be
male with good quality of life, and they more fre-
quently admitted having negative attitudes
 2004 Blackwell Publishing Ltd, Journal of Clinical Pharmacy and Therapeutics, 29, 405–415
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Table 1. Mean values of SF36
dimensions, and four attitudes
towards psychotropic drugs. Dis-
tribution of socio-demographic and
medical characteristics of psycho-
tropic drug non-consumers, con-









0 (n = 125)
Percentage
Gender
Male 55Æ4 44Æ4 28Æ0
Female 44Æ6 55Æ6 72Æ0
Marital status
Married/family 83Æ5 83Æ1 78Æ4
Single/divorced/widowed 16Æ5 16Æ9 21Æ6
Education level
Elementary school 38Æ3 43Æ0 39Æ2





Employed/workers 23Æ1 20Æ4 17Æ6
Non-active subjects 22Æ4 30Æ3 20Æ8
Chronic disease
Yes 27Æ2 40Æ8 40Æ0
Neuroleptic consumption
Yes – 3Æ5 4Æ8
Anxiolytic consumption
Yes – 61Æ3 41Æ6
Hypnotic consumption
Yes – 25Æ4 12Æ0
Antidepressant consumption
Yes – 33Æ8 38Æ4
Mean (SD)
Age (years) 52Æ9 (4Æ3) 53Æ9 (4Æ6) 53Æ1 (4Æ5)
SF36 dimensionsa
Physical functioning 91Æ4 (11Æ2) 85Æ4 (17Æ5) 87Æ9 (13Æ2)
Role limitation cause
by physical problem
87Æ5 (25Æ7) 72Æ5 (35Æ5) 79Æ9 (29Æ0)
Role limitation cause
by emotional problem
86Æ1 (27Æ1) 64Æ2 (39Æ2) 73Æ6 (36Æ7)
Social functioning 83Æ6 (18Æ8) 65Æ9 (24Æ4) 71Æ4 (21Æ6)
Bodily pain 69Æ2 (20Æ7) 59Æ3 (20Æ7) 62Æ4 (18Æ5)
Mental health 70Æ9 (16Æ4) 53Æ1 (19Æ8) 58Æ9 (18Æ3)
Vitality 63Æ1 (15Æ9) 49Æ8 (18Æ9) 53Æ0 (16Æ8)




50Æ5 (20Æ0) 70Æ7 (19Æ1) 63Æ5 (17Æ7)
Score2: explicit dependency 77Æ7 (24Æ9) 73Æ2 (28Æ9) 61Æ3 (28Æ2)
Score3: negative towards
psychotropic drugs
72Æ1 (21Æ0) 57Æ4 (27Æ1) 66Æ5 (23Æ8)
Score4: implicit dependency 60Æ5 (17Æ6) 68Æ6 (18Æ1) 60Æ9 (17Æ9)
a100 = best quality of life/0 = poorest quality of life.
b0 = less in agreement/100 = more in agreement.
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Table 2. Odds ratio and adjusted odds ratio for continuous consumers relative to occasional consumers
Univariate logistic regression Multivariate logistic regression
N Odds ratio [CI 95%] N Odds ratio [CI 95%] Step n
SF36a 261
Physical functioning 266 0Æ90 [0Æ77–1Æ05]
Role limitation cause by
physical problem
265 0Æ93 [0Æ86–1Æ00]
Role limitation cause by
emotional problem
266 0Æ93 [0Æ89–0Æ99]*
Social functioning 265 0Æ90 [0Æ81–1Æ00]
Bodily pain 266 0Æ93 [0Æ82–1Æ05]
Mental health 266 0Æ85 [0Æ75–0Æ97]* 0Æ83 [0Æ71–0Æ97]* 8
Vitality 266 0Æ92 [0Æ81–1Æ06]
General health 266 0Æ87 [0Æ74–0Æ98]*
Attitudesa
Score 1: positives towards
psychotropic drugs
264 1Æ22 [1Æ07–1Æ40]** 1Æ36 [1Æ15–1Æ60]*** 2
Score 2: explicit dependence 264 1Æ16 [1Æ06–1Æ26]*** 1Æ20 [1Æ08–1Æ34]*** 1
Score 3: negatives towards
psychotropic drugs
264 0Æ88 [0Æ79–0Æ96]**
Score 4: implicit dependence 264 1Æ28 [1Æ10–1Æ48]*** 1Æ28 [1Æ08–1Æ53]** 4
Age (years)
46–52 130 1 128
53–62 137 1Æ21 [0Æ74–1Æ96] 133
Gender
Male 98 1 98 1
female 169 0Æ49 [0Æ29–0Æ82]** 163 0Æ37 [0Æ20–0Æ69]** 3
Marital status
Married/family 216 1 212
Single/divorced/widowed 51 0Æ74 [0Æ40–1Æ36] 49
Education level
Elementary school 110 1 107




147 1 145 1
Employed/workers 51 1Æ45 [0Æ76–2Æ76] 50 1Æ99 [0Æ91–4Æ34]
Non-active subjects 69 1Æ82 [1Æ01–3Æ27] 66 2Æ63 [1Æ29–5Æ37] * 7
Chronic disease
No 159 1 154
Yes 108 1Æ04 [0Æ63–1Æ69] 107
Neuroleptic consumption
No 256 1 250
Yes 11 0Æ72 [0Æ21–2Æ45] 11
Anxiolytic consumption
No 128 1 123 1
Yes 139 2Æ22 [1Æ36–3Æ63]** 138 2Æ52 [1Æ39–4Æ57]** 5
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towards psychotropics and dependency. OCs were
more likely to be female, with fairly high social
status, reporting a chronic pathology, having
intermediate quality of life and denying depend-
ency on this type of medication. CCs tended to be
males with no professional activity, poor quality of
life scores, in particular in the mental and per-
ceived health dimensions, and they entertained
positive attitudes towards psychotropics and
accepted dependency.
In a linear and one-directional conception of the
biomedical model, recourse to psychotropic medi-
cation has been viewed as a consequence of mental
disorders. While recognizing the contributions of
classical factors, the present study, with its socio-
cultural approach, is closer to providing an
explanatory model that is both multifactorial and
interactionist. Men and women undergoing biolo-
gical, sociological and psychological influences do
not experience adverse events in a passive manner.
The study subjects adopted behavioural strategies
in which quality of life and attitudes towards
psychotropics and dependency predisposed NCs
to non-consumption, played a part in consumption
for OCs, and reinforced CCs in the maintenance of
their consumption of the psychotropic drugs.
Non-consumers
Non-consumers had the best quality of life. They
had negative attitudes towards psychotropics and
dependency. They recognized the iatrogenic risk of
dependency inherent in this type of medication.
These results are in line with those published (7, 8).
This interaction of psychological with social factors
certainly curbed recourse to psychotropic medica-
tion in this group of subjects.
Occasional consumers
Occasional consumers tended to be women
reporting a chronic pathology; probably related to
problems associated with the menopause and
arthritis, among others. Thus their quality of life
was intermediate and lower than for the NC group.
OCs optimized their quest for well-being by limit-
ing their consumption to a socially acceptable level.
They adopted an attitude of denial with respect to
dependency, whether explicit (e.g. they do not
agree that these medications lead to dependency)
or implicit (e.g. they do not subscribe to the idea
that they would like to do without this medication).
These attitudes contrast with those found in the NC
and CC groups, and were less positive than for the
CC group. Another study on the same OC group
(16) showed that these subjects were more fre-
quently in tune with the statements: ‘when you feel
better, you tend to stop taking the medication’;
‘when this medication is taken for too long a period
it is less efficient’; ‘taking this medication means
you are ill’; ‘this type of medication has undesir-
able or unpleasant effects’.
Table 2. Continued
Univariate logistic regression Multivariate logistic regression
N Odds ratio [CI 95%] N Odds ratio [CI 95%] Step n
Hypnotic consumption
No 216 1 210 1
Yes 51 2Æ49 [1Æ28–4Æ83]** 51 3Æ00 [1Æ37–6Æ57]** 6
Antidepressant consumption
No 171 1 167
Yes 96 0Æ82 [0Æ49–1Æ35] 94
Univariate logistic regression for 142 continuous consumers according to 125 occasional consumers. ***P < 0Æ001; **P < 0Æ01; *P < 0Æ05.
Degree of significance for maximum likelihood X2.
Multivariate logistic regression for 139 continuous consumers according to 122 occasional consumers. Step-by-step procedure.
***P < 0Æ001; **P < 0Æ01; *P < 0Æ05. Degree of significance for maximum likelihood X2 at the last step/goodness of fit = 0Æ07/Hosmer-
Lemeshow = 0Æ1.
aOdds ratio for an increase of 10 points.
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Table 3. Univariate nominal poly-
chotomous logistic regression for
continuous and occasional psycho-











Physical functioning 598 0Æ74 [0Æ64–0Æ85] 0Æ82 [0Æ70–0Æ95] ***
Role limitation cause
by physical problem
593 0Æ85 [0Æ80–0Æ90] 0Æ91 [0Æ85–0Æ97] ***
Role limitation cause
by emotional problem
596 0Æ83 [0Æ78–0Æ88] 0Æ89 [0Æ84–0Æ95] ***
Social functioning 596 0Æ69 [0Æ63–0Æ76] 0Æ76 [0Æ69–0Æ84] ***
Bodily pain 595 0Æ79 [0Æ71–0Æ87] 0Æ85 [0Æ76–0Æ94] ***
Mental health 596 0Æ59 [0Æ52–0Æ66] 0Æ68 [0Æ60–0Æ77] ***
Vitality 597 0Æ65 [0Æ58–0Æ73] 0Æ70 [0Æ62–0Æ80] ***
General health 600 0Æ64 [0Æ57–0Æ73] 0Æ75 [0Æ66–0Æ85] ***
Attitudesa
Score 1: positives towards
psychotropic drugs
566 1Æ90 [1Æ60–2Æ10] 1Æ50 [1Æ30–1Æ70] ***
Score 2: explicit
dependence
566 0Æ86 [0Æ79–0Æ94] 0Æ74 [0Æ68–0Æ81] ***
Score 3: negatives towards
psychotropic drugs
566 0Æ71 [0Æ64–0Æ78] 0Æ82 [0Æ75–0Æ91] ***
Score 4: implicit
dependence
566 1Æ20 [1Æ10–1Æ40] 0Æ92 [0Æ81–1Æ10] ***
Age (years)
46–52 300 1 1
53–62 301 1Æ20 [0Æ81–1Æ80] 0Æ99 [0Æ65–1Æ50]
Gender:
Male 283 1 1
Female 318 1Æ60 [1Æ00–2Æ30] 3Æ20 [2Æ00–5Æ00] ***
Marital status:
Married/family 495 1 1
Single/divorced/widowed 106 1Æ03 [0Æ62–1Æ75] 1Æ38 [0Æ83–2Æ32]
Education level
Elementary school 238 1 1
Secondary school/
University





Employed/workers 128 0Æ98 [0Æ59–1Æ60] 0Æ68 [0Æ39–1Æ20]
Non-active subjects 144 1Æ50 [0Æ94–2Æ40] 0Æ82 [0Æ49–1Æ40]
Chronic disease
No 402 1 1
Yes 199 1Æ80 [1Æ20–2Æ80] 1Æ80 [1Æ20–2Æ70] **
Univariate nominal polychotomous logistic regression for 142 continuous and 125
occasional consumers according to 334 non-consumers.
***P < 0Æ001; **P < 0Æ01; *P < 0Æ05. Degree of significance for global maximum likelihood X2
test according to non-consumers, and continuous and occasional consumers.
aOdds ratio for an increase of 10 points.
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Table 4. Multivariate nominal polychotomous logistic regression for continuous and occasional psychotropic drugs







consumers [CI 95%] P Step n
SF36a 552
Physical functioning
Role limitation cause by
physical problem




Mental health 0Æ54 [0Æ46–0Æ65] 0Æ67 [0Æ57–0Æ80] *** 2
Vitality.
General health 0Æ78 [0Æ65–0Æ94] 0Æ82 [0Æ68–0Æ98] * 6
Attitudesa
Score 1: positives towards
psychotropic drugs
1Æ90 [1Æ70–2Æ30] 1Æ40 [1Æ20–1Æ60] *** 1
Score 2: explicit dependence 1Æ00 [0Æ89–1Æ10] 0Æ80 [0Æ72–0Æ89] *** 4
Score 3: negative towards
psychotropic drugs
0Æ73 [0Æ65–0Æ83] 0Æ85 [0Æ76–0Æ97] *** 3





Male 262 1 1











Employed/workers 117 0Æ67 [0Æ34–1Æ30] 0Æ36 [0Æ18–0Æ72]
Non-active subjects 134 1Æ40 [0Æ73–2Æ80] 0Æ58 [0Æ30–1Æ10] ** 7
Chronic disease
No 363 1 1
Yes 189 1Æ80 [1Æ00–3Æ2] 1Æ90 [1Æ10–3Æ30] * 9
Multivariate nominal polychotomous logistic regression for 139 continuous and 122 occasional consumers according to 291 non-
consumers. Step-by-step procedure.
***P < 0Æ001; **P < 0Æ01; *P < 0Æ05. Degree of significance at the final step for maximum likelihood X2 test according to non-consumers,
and continuous and occasional consumers.
a Odds ratio for an increase of 10 points.
Goodness of fit = 1.
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Thus whenever there is deterioration in psy-
chological health, these attitudes lead the OC
group to use psychotropic drugs, but to cease
consumption as soon as well-being was re-estab-
lished so as to protect against side-effects. This
occasional use, demonstrates a will to preserve
autonomy while resorting to medication. The
denial of dependency or addiction enabled the OC
group to believe they could control consumption.
A British study (6) on the role of socio-cultural
determinants in psychotropic consumption among
60-year-old consumers of at least 6-month standing
highlighted three categories of consumer attitudes:
fuel, tonic and food. These observations are close to
those of the present study, with the OCs having
characteristics close to those of the ‘tonic’ group
(34%). This label covers users who considered that
this type of medication was a sort of tonic leaving
them to have full control over their medical con-
sumption (doses, frequency, etc.). They saw the
action of psychotropics as being on them rather
than on people around them, thus boosting their
independence and autonomy with respect to the
opinions of others. They were liable to consider
that psychotropics had a psychological effect, and
to doubt the pharmacological effects of the medi-
cation. For them, psychotropics are designed above
all to stimulate and act as a tonic when a person is
temporarily depressed, anxious or tense.
Continuous consumers
Continuous consumers had the poorest quality of
life of the three study groups. This interaction
between poor quality of life and positive attitudes
appears to sustain use of psychotropic drugs over
long periods. The same CC group, in the study
quoted earlier, more frequently subscribed to the
statements ‘when you have problems, you tend to
resort to psychotropics’; ‘it would be nice to do
without this sort of medication’; ‘you can’t do
without this medication’; ‘you become dependent
on this type of medication’; ‘I have a good opinion
of this sort of medication’ (16). It would thus
appear that their behaviour was built around a
feeling of resignation and acceptance of depend-
ency, and a generally fairly favourable attitude
towards psychotropics, which provide an answer
to a deficit in well-being, or to needs arising from
physical and/or psychological dependency.
More than a third of the CC group had taken
psychotropics daily, in particular hypnotics and
anxiolytics. Only 30 stated they were able to do
without the drugs (11). The chronic nature of con-
sumption of psychotropics is therefore not a spe-
cifically female phenomenon as has been suggested
in the literature (4). In the present study, men were
observed to be consumers less frequently, but
when they did consume, it was more likely to be on
a continuous basis. The study observations on CCs
are close to those in the ‘fuel’ group (44%) and the
‘food’ group identified in the British study (6). The
‘fuel’ group included consumers who view medi-
cation as a form of fuel; they had limited control
over their consumption and considered that the
effects of the medication were due to habit and
probably of a psychological nature. But psycho-
tropics occupied a very important place in their
lives because they felt that the medication enabled
harmonious relationships with others, acting as a
fuel that made it possible to ‘run’ or function as
expected by people around them. For this group,
the medication was not viewed as essential, but as
very valuable assistance. The ‘food’ group was
formed by consumers who viewed medication as a
form of food. These were subjects who had the least
control over their consumption, and showed strong
psychological dependency. They considered that
the medication acted on others as much as it did on
them. It was taken at precise, fixed intervals, in
strict compliance. Little by little the medication
became a sort of food symbol, essential to life.
This last point makes it easier to understand the
complexity of the issues discussed on the use of
this type of medication as an instrument facilitating
social relationships and conformity with the norm.
The social requirement is part of the possible
explanations for recourse to psychotropic drugs for
the purpose of maintaining or achieving acceptable
quality of life (17).
The main limitations of this work relate to the
way in which the samples were selected. As the
subjects were drawn from the SUVIMAX cohort,
they were, ‘health-conscious’, and thus not repre-
sentative of the general French population. Their
socio-demographic characteristics are relatively
homogeneous with respect to age, socio-profes-
sional category, family situation, and educational
level. This homogeneity may have led to a lack of
power in the analysis of the factors selected.
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PERSPECTIVES
Assessment of quality of life and evaluation of
attitudes towards psychotropics and dependency
provide valuable data for exploring determinants
of use of psychotropic medication. The present
study suggests the following:
• For health system users: all programmes
designed to promote optimum use of medication
prescribed, in particular those aimed at reducing
over-consumption, should be based on results
derived from studies on the influence of popular
beliefs on consumption behaviours.
• For patients: all therapeutic education should
emphasize the side-effects of psychotropic
medication and compliance with medical rec-
ommendations. Responding to patients’ expec-
tations improves the practitioner–patient
relationship, and improves patient satisfaction
with care received. These in turn lead to better
observance of medical recommendations, and
reduce the number of medical consultations (18).
• For practitioners: medical training programmes
should provide an analysis of popular beliefs,
and explore behavioural variations associated
with quality of life. Assessment of quality of life
and understanding of attitudes towards psy-
chotropics can provide important insights for
those in charge of health promotion programmes
so that intervention strategies can be improved
and new ones developed. Preventive education
and follow-up of therapy may be better suited to
the needs of patients.
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